EURECA-m CME Course in Iasi Last September 5th and 6th, 2014, Prof. Adrian Covic organized, as former EURECA-m Board Member, the 3rd EURECA-m CME Course of the year in Iasi, Romania. The CME discussed the cardiovascular risk factors in chronic kidney disease (CKD) in all aspects with 14 talks by experts in the field grouped into 4 sessions and various lectures as below: Measuring renal function and integrating cardiovascular risk factors in CKD: a reappraisal Pulmonary congestion in CKD: an integrator of LV disorders and volume overload New methods to evaluate cardiac and fluid status in dialysis Cardiac evaluation of transplant candidates – what test for what person? Bioimpedance and lung comments guided management in dialysis patients. Preliminary results of the BUST trial Inflammation and nutrition in CKD, always at center stage Inflammasome and cardio-renal risk in CKD Aldosterone antagonism – better than ACEI? Stroke risk: a crucial, over looked problem in CKD Clinical epidemiology of hypertension and hypertension related risk in CKD Nutrition and cardiovascular disease in CKD: any room for intervention? Visit to visit variability in CKD Novel pharmacological treatments of hypertension Update on renal ablation for hypertension CKD-MBD in cardiovascular and renal medicine: two steps forward and one back? Re-appraisal about the role of PTH in Cardiovascular Disease and in CKD. Pros and cons debate: Phosphate as a cardiovascular risk factor: is the evidence solid enough? (Pros) Any evidence linking CKD-MBD to hard outcomes? (Cons) The discussion about cardio-renal link is very complex: there is a bi-directionality link, loss of kidney function may trigger cardiovascular disease and cardiovascular diseases may also engender kidney damage. The experts also discussed the importance of inflammation and nutrition is CKD patients as well as about the volume control by bio-impedence and thorax ultrasound in CKD on outcome. They also provided about the importance of visit to visit blood pressure variability on long-term outcome in CKD patients and also discussed novel pharmacological and other treatment (renal denervation) modalities of hypertension. Lastly, they also provided an update on vascular calcification (including phosphate, FGF-23, klotho).
|